Gansu Screens Ninth Batch of Drug Sunshine Listing Applications – Only 229 of 595 Pass Formal Review as Appeal Window Closes

Leave a reply

Lanzhou, China – 18 Sep 2026 – The Gansu Public Resources Trading Center publicized the formal review results of the ninth batch of new drug sunshine listing applications for 2026, disclosing that of 595 products submitted through the national joint review mechanism (联审通办) and the provincial bidding‑and‑procurement management subsystem as of 10 September 2026, only 229 qualified for platform listing while 366 failed the screening. The publicity period runs 20–22 September 2026, with online appeals due by 24:00 on 22 September 2026.

Policy Snapshot

ItemDetail
AgencyGansu Public Resources Trading Center; supervised by the Gansu Provincial Healthcare Security Bureau
DocumentPublicity of Formal Review Results – Ninth Batch of New Drug Sunshine Listings, 2026
Legal BasisGansu Service Guide for the Drug & Medical Consumables Procurement Management Subsystem (v1.0); Gansu Drug Listing/Delisting Rules
Applications Received595 (national joint review + provincial subsystem, as of 10 Sep 2026)
Passed Formal Review229 (≈ 38.5 % pass rate)
Failed Formal Review366 – itemized in the annexed publicity table (.xls)
Publicity Period20–22 Sep 2026
Appeal Deadline24:00, 22 Sep 2026, online only
ContactsBusiness: 0931‑2909290 / 2909266 / 2909265; Supervision: 0931‑8127609 (Provincial Healthcare Security Bureau)

Review Results & Compliance Requirements

  • Formal Review Outcomes: The 229 qualifying products will proceed to sunshine listing on the provincial platform, subject to completion of the publicity period; the 366 rejected products are listed in the annexed Formal Review Results Publicity Table, giving affected manufacturers a clear, product‑level basis for appeal.
  • Price Declaration Undertakings: Listing prices are self‑declared by enterprises under the good‑faith principle and must not exceed Gansu’s provincial price‑management requirements – placing documentation and pricing integrity squarely on applicants.
  • Cross‑Province Price‑Linkage Rule: If a listed drug’s price is reduced in any other province, the manufacturer must proactively apply for a matching price cut in Gansu within one month – failure to do so triggers suspension of trading qualification, extending the nationwide price‑linkage discipline into Gansu’s procurement channel.
  • Appeals Strictly Online: Objections must be filed via the “Appeal & Query” module under the “New Drug Listing Application” menu of the Gansu National Healthcare Insurance Information Platform procurement subsystem; paper and email submissions are not accepted, and non‑conforming filings will be rejected with any resulting losses borne by the enterprise.

Market Impact & Outlook

  • Selective Gatekeeping: A ≈ 38.5 % pass rate (229 of 595) signals rigorous formal screening in Gansu, reinforcing that completeness and accuracy of submission dossiers – not price alone – determine platform access.
  • National‑Provincial Convergence: The batch combined applications from the national joint review mechanism with the provincial subsystem, reflecting China’s ongoing integration of drug procurement access points across provinces.
  • Pricing Discipline Tightening: The one‑month cross‑province price‑adjustment obligation, backed by trading suspension, aligns Gansu with the hardening nationwide enforcement of external‑reference pricing for listed drugs.
  • Immediate Action Window: With the publicity period and appeal deadline both closing on 22 September 2026, manufacturers among the 366 rejected products face a same‑week turnaround to challenge results or prepare compliant resubmissions in future batches.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding appeal outcomes, listing approvals, price‑adjustment obligations, and trading‑qualification status for drug products in Gansu Province. Actual results may differ due to risks including appeal handling decisions, enterprise remediation progress, and subsequent policy adjustments by the Gansu Public Resources Trading Center and the Provincial Healthcare Security Bureau.-China Health Reform Pulse

Policy Source: https://sjfz.ggzyjy.gansu.gov.cn:19002/#/details-medicine?params=H4sIAAAAAAAAA6tWykxRslIyNLewNDcyNTSyMDc0VaoFAElMeS4WAAAA&pop=true

Hunan Rolls Out 2026 TCM Pricing Governance Results – 10x Anchor‑Price Deadline, Risk Flags, and Listing Suspensions

Leave a reply

Changsha, China – 18 Sep 2026 – The Hunan Provincial Healthcare Security Bureau issued Notice Xiang Yi Bao Zhao Cai Han [2026] No. 114, implementing the results of its 2026 province‑wide price governance campaign for traditional Chinese medicine (TCM) decoction pieces and formula granules. The notice applies price‑risk markings to flagged products, orders manufacturers to cut listed prices exceeding 10 times the anchor price by 17:00 on 24 September 2026, imposes listing suspensions of at least three months on non‑compliant products, and confirms that new listing applications resume on 1 October 2026.

Policy Snapshot

ItemDetail
AgencyHunan Provincial Healthcare Security Bureau (China)
DocumentNotice on Implementing the 2026 Price Governance Results for TCM Decoction Pieces and Formula Granules (Xiang Yi Bao Zhao Cai Han [2026] No. 114)
Legal BasisNotice on Launching Price Governance of Listed Prices for TCM Decoction Pieces and Formula Granules (Xiang Yi Bao Zhao Cai Han [2026] No. 103)
ScopeTCM decoction pieces and formula granules listed on Hunan’s provincial procurement platform
Key Deadline17:00, 24 Sep 2026 – cut listed prices to within 10x the anchor price
SanctionsListing suspension (from 3 months) for missed price cuts, unestablished distribution relationships, or non‑conforming invoice information
Appeal Window3 months from the price‑risk‑flagging date, via the appeal module of the procurement subsystem
Channel ReopeningListing applications and filing‑to‑sunshine‑listing conversions accepted again from 1 Oct 2026
Affected ProductsNot disclosed in the notice body; itemized in five annexed lists

Governance Measures in Detail

  • Price‑Risk Flagging: Products whose manufacturers lowered listed prices within the designated window have been cross‑checked against provincial transaction data and marked with price‑risk flags in the bidding‑and‑procurement subsystem of the Hunan Healthcare Insurance Information Platform. Enterprises may review their flags directly; companies that later cut prices into compliance will have flags adjusted periodically under the stated rules.
  • Anchor‑Price Correction (10x Rule): Listed prices more than 10x the anchor price (10x itself excluded) fall within the correction scope. Manufacturers must reprice by the 24 September deadline; products that miss it – absent a pending complaint or appeal – will be suspended from the platform, while products under active appeal will be disposed of per the appeal handling opinions.
  • Compliance‑Based Suspensions: Separate suspensions (effective from the notice’s publication date, running at least three months) apply to products whose enterprises failed to establish required distribution relationships or whose invoice information remained non‑conforming after self‑inspection. Enterprises that subsequently remediate may apply for listing restoration.
  • Due‑Process Safeguards: A three‑month appeal window via the subsystem’s appeal module preserves a formal challenge path for companies disputing their risk flags.
  • Application Resumption: From 1 October 2026, Hunan resumes accepting new listing applications for TCM decoction pieces and formula granules, as well as conversions from filing to sunshine listing – signaling a return to normal channel operations after the governance round.

Market Impact & Outlook

  • Compliance Crunch: Manufacturers of flagged SKUs face a roughly six‑day repricing window between the notice date and the 24 September deadline – a tight turnaround that will test internal pricing governance at TCM producers selling into Hunan.
  • TCM Price Discipline Trend: The anchor‑price mechanism extends the centralized‑procurement playbook from chemical drugs into the historically fragmented TCM decoction‑pieces and formula‑granules market, where wide price dispersion across provinces has drawn sustained regulatory scrutiny.
  • Supply Continuity Risk: Suspensions of three months or longer could create temporary gaps in affected SKUs at Hunan public medical institutions; hospitals and distributors are advised to review the five annexed lists covering price‑correction products, missing distribution relationships, and invoice non‑conformities.
  • Structural Signal: Pairing enforcement suspensions with a firm 1 October reopening suggests Hunan views this round as a market‑clearing exercise rather than a prolonged freeze, with ongoing periodic flag adjustments keeping price discipline continuous.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory deadlines, appeal outcomes, suspension durations, and the resumption of listing applications for TCM decoction pieces and formula granules in Hunan Province. Actual results may differ due to risks including appeal handling decisions, enterprise remediation progress, and subsequent policy adjustments by the Hunan Provincial Healthcare Security Bureau.-China Health Reform Pulse

Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202609/t20260918_34067089.html

CPC Organization Department and NHC Issue Revised Management Measures for Public Hospital Leadership – Eight‑Chapter Framework Resets Qualifications, Terms, Assessment and Exit Rules Nationwide

Leave a reply

Beijing, China – 12 Aug 2026 – The Organization Department of the CPC Central Committee and China’s National Health Commission (NHC) promulgated the revised Management Measures for Leaders in Public Medical Institutions (originally enacted 13 Jan 2017; revised 22 Jul 2026), an eight‑chapter, 35‑article regulation governing the selection, tenure, assessment, incentives, supervision and exit of leadership teams in public hospitals — effective from the date of publication and publicly released via China Organization and Personnel News on 18 Sep 2026.

Policy Snapshot

ItemDetail
AuthoritiesOrganization Department of the CPC Central Committee; National Health Commission (NHC)
DocumentManagement Measures for Leaders in Public Medical Institutions (2026 revision)
Revision HistoryEnacted 13 Jan 2017 (Organization Dept + former NHFPC); revised 22 Jul 2026; published 12 Aug 2026
ScopeLeadership team members of public hospitals run by governments at county level and above, public institutions, social groups and other social organizations; SOE‑run public hospitals apply the measures by reference
Structure8 chapters, 35 articles – general provisions, qualifications, selection & appointment, assessment, career development & incentives, supervision, exit, supplementary provisions
Effective DateFrom date of publication (12 Aug 2026)

Qualification & Selection Framework

  • Baseline Qualifications: Generally a bachelor’s degree or above; 5+ years of medical/health or related management experience — 10+ years for leaders of tertiary hospitals; deputy‑to‑principal promotion requires 2+ years in a deputy role, and lower‑principal to higher‑deputy requires 3+ years.
  • Technical‑to‑Management Tracks: Professionals from medical, pharmacy, nursing, technical and research posts must hold corresponding professional technical appointments — e.g., senior or 5+ years associate‑senior titles for Grade 4+ management posts and for tertiary hospital presidents and business‑line deputies; relaxed thresholds apply in hardship and remote areas.
  • Sourcing Channels: Selection generally via internal recommendation or external dispatch, with competitive appointment and open recruitment permitted to widen the talent pool; presidents and business deputies generally come from the medical/health sector.
  • Appointment Modes: Tenure by election, appointment or engagement (聘任制) — leaders produced through open selection generally serve under the engagement system, with flexible pay and term arrangements allowed.

Tenure, Assessment & Compensation

  • Term Limits: Terms of 3–5 years; continuous service in the same post generally capped at 10 years (extendable with approval); leaders are expected to serve out at least one full term.
  • Public‑Welfare‑Oriented Targets: Term objectives embed medical quality and safety, cost control, public‑welfare duties, lawful management, medical ethics and Party building; tertiary hospitals add digital‑intelligent construction and discipline/team development; TCM hospitals must reflect traditional Chinese medicine’s distinctive advantages.
  • Assessment Ratings: Teams graded excellent/good/average/poor (excellent ≤ 30 % of teams assessed); individuals graded excellent/qualified/basically qualified/unqualified (excellent ≤ 25 %), with cascading caps when a team is rated average or poor.
  • Time Commitment & Pay: Leaders must devote ≥ 4/5 of statutory working time to hospital management; compensation ties to assessment and keeps a reasonable ratio to average staff income — directly linking leader income to hospital economic revenue is strictly prohibited, with an annual salary system permitted where conditions allow.
  • Development & Rotation: Full training coverage every 5 years; structured exchanges across hospital tiers and regions — urban tertiary hospitals with county hospitals, eastern with central/western institutions — aligned with Healthy China resource‑balancing goals.

Supervision, Recusal & Exit

  • Expanded Oversight: Inspection tours and audits target procurement, drugs and devices, infrastructure, service outsourcing, medical insurance fund use, income distribution, title appointments and “ghost payroll” issues, alongside democratic centralism and “three majors and one large” decision‑making compliance.
  • Recusal Rules: Leaders must recuse themselves where interests involve directly supervised graduate students, their own academic teams or other conflicts affecting impartial duty.
  • Exit Mechanisms: Age‑limit retirement with possible extension for outstanding principals; adjustment of leaders deemed unfit for current posts (e.g., medical ethics violations, poor handling of major emergencies); a resignation system explicitly guards against “revolving door” and “escape‑style resignation” problems, while exiting leaders may transition to professional technical roles.

Market Impact & Outlook

  • Professionalization of Hospital Management: Engagement‑based appointments, 5‑year training cycles and professional‑track transitions signal a deliberate build‑out of a professional public hospital leadership corps.
  • Anti‑Profit Reinforcement: The hard ban on tying leader pay to hospital revenue strengthens the public‑welfare orientation — constraining volume‑driven revenue behavior with downstream effects on device and drug utilization patterns.
  • Talent Redistribution: Mandatory rotation between tertiary, county, eastern and western hospitals operationalizes the policy goal of expanding and sinking quality medical resources.
  • Compliance Bar Rises: The detailed supervision catalogue raises accountability for hospital leadership — and by extension for suppliers’ interactions with procurement, IT and infrastructure decision‑makers.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding implementation of the revised management measures, including leadership selection, assessment outcomes and compensation reforms. Actual execution depends on interpretation by the Organization Department and NHC, local implementation rules and individual institutional practice, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.nhc.gov.cn/wjw/mtbd/202609/7e830145ff3144d8b8609b5616c09793.shtml